Current Report Filing (8-k)
April 06 2018 - 6:30AM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM
8-K
CURRENT
REPORT
Pursuant to Section 13 or 15(d)
of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): April 6, 2018 (April 3, 2018)
MIRAGEN THERAPEUTICS, INC.
(Exact name of registrant as specified in its charter)
|
|
|
|
|
Delaware
|
|
001-36483
|
|
47-1187261
|
(State or other jurisdiction
of incorporation)
|
|
(Commission
File Number)
|
|
(IRS Employer
Identification No.)
|
|
|
|
6200 Lookout Rd.
Boulder, CO
|
|
80301
|
(Address of principal executive offices)
|
|
(Zip Code)
|
Registrants telephone number, including area code: (720)
643-5200
(Former name or former address, if changed since last report)
Check the appropriate box below if the Form
8-K
filing is intended to simultaneously satisfy the filing obligations of
the registrant under any of the following provisions:
☐
|
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
|
☐
|
Soliciting material pursuant to Rule
14a-12
under the Exchange Act (17 CFR
240.14a-12)
|
☐
|
Pre-commencement
communications pursuant to Rule
14d-2(b)
under the Exchange Act (17 CFR
240.14d-2(b))
|
☐
|
Pre-commencement
communications pursuant to Rule
13e-4(c)
under the Exchange Act (17 CFR
240.13e-4(c))
|
Indicate by check mark whether the registrant is an emerging growth company as defined
in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule
12b-2
of the Securities Exchange Act of 1934 (§
240.12b-2
of this chapter).
Emerging growth company ☒
If an emerging
growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange
Act. ☐
Section 1 Registrants Business and Operations
Item 1.01 Entry into a Material Definitive Agreement.
On April 3, 2018, Miragen Therapeutics, Inc., a Delaware corporation (the
Company
), entered into a seventh amendment (the
Amendment
) to that certain License and Collaboration Agreement (the
Servier Agreement
) between the Company and Les Laboratoires Servier and Institut de Recherches Servier (collectively,
Servier
).
Among other things, the Amendment updates the development plan for the Companys product candidate,
MRG-110,
which is an inhibitor of
microRNA-92
and is being developed under the Servier Agreement for the treatment of heart failure and other ischemic disease. The Amendment,
among other things, (i) updates the development plan for
MRG-110
and cost-sharing provisions associated therewith, (ii) provides for specified development cost reimbursement by Servier to the Company
following a determination by a joint committee established by the parties under the Servier Agreement that the outcome of a specified portion of a Phase 1 clinical trial has met its primary end point, and (iii) provides for additional
development plan cost reimbursement by Servier to the Company following a determination by a joint committee established by the parties under the Servier Agreement that a product candidate targeting
microRNA-92
will proceed into a Phase 2 clinical trial.
The foregoing description of the Amendment is not
complete and is qualified in its entirety by reference to the full text of the Amendment. The Company anticipates filing a copy of the Amendment with its periodic report on Form
10-Q
for the quarter ended
March 31, 2018.
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned
hereunto duly authorized.
|
|
|
|
|
|
|
|
|
|
|
Miragen Therapeutics, Inc.
|
|
|
|
|
Date: April 6, 2018
|
|
|
|
By:
|
|
/s/ Jason A. Leverone
|
|
|
|
|
|
|
Jason A. Leverone
Chief Financial
Officer
|
Miragen Therapeutics (NASDAQ:MGEN)
Historical Stock Chart
From Mar 2024 to Apr 2024
Miragen Therapeutics (NASDAQ:MGEN)
Historical Stock Chart
From Apr 2023 to Apr 2024